This page walks through what each test contributes, how scores built from ordinary labs estimate fibrosis, where elastography fits alongside a blood draw, and which findings are worth raising with a clinician. It is educational and not medical advice.
Cirrhosis describes the late stage of chronic liver scarring, in which repeated injury replaces working liver tissue with fibrous bands and regenerative nodules that stiffen the organ and distort blood flow through it.
The liver tolerates a great deal before it reaches that point. Injury from long-term alcohol intake, fat accumulation in liver cells, chronic viral hepatitis, autoimmune liver conditions and inherited iron or copper handling disorders all drive the same basic repair loop. Cells are damaged, the repair machinery lays down collagen, and when the injury continues the scaffolding thickens instead of resolving. Over years the architecture changes shape. Blood that should pass easily from the gut through the liver meets resistance, pressure rises in the portal vein, and the organ's chemical work, making proteins, clearing bilirubin, processing substances absorbed from the gut and building clotting factors, becomes harder to sustain.
Clinicians usually split the picture in two. Compensated means the scarring is present but the liver is still keeping up, and a person may feel well. Decompensated means complications have appeared, such as fluid collecting in the abdomen, bleeding from distended veins, yellowing of the skin or eyes, or confusion. Blood work behaves differently in those two states, which is one reason a single panel is read against symptoms, history and imaging rather than on its own.
That split also explains why liver labs carry two different kinds of information. Some tests report injury, meaning how much enzyme is leaking out of damaged cells. Others report function, meaning how well the liver is still doing its jobs. A cirrhosis workup is largely an exercise in reading the second group against the first.
Albumin is the main protein the liver makes and releases into the blood, so its level is one of the standard readouts of liver synthetic function. When liver tissue is heavily scarred, production can fall, and albumin drifts downward over months rather than hours because the protein turns over slowly. It is not a liver-specific marker. Inflammation, low protein intake, protein loss through the kidneys and gut disorders can all pull it down, which is why a low result prompts a wider look rather than a conclusion. The dedicated albumin guide covers what the test measures, how it is run, and how to read a single result.
A liver workup pairs enzymes with function tests and a full blood count, because hepatic cirrhosis lab values only make sense as a group. Below are the tests most often ordered together, with ranges stated as typical lab reference ranges.
| Test | What it reflects | Typical lab reference range | FitScript optimal range |
|---|---|---|---|
| Albumin | Protein made by the liver, a marker of synthetic function | 3.5 to 5.5 g/dL | 4.2 to 5 g/dL |
| ALT | Enzyme concentrated in liver cells, released when they are injured | roughly 7 to 56 U/L | Standard range only |
| AST | Enzyme found in liver, muscle, heart and red cells | roughly 10 to 40 U/L | Standard range only |
| ALP | Enzyme linked to bile flow and to bone | roughly 40 to 130 U/L | Standard range only |
| GGT | Enzyme of the small bile ducts, sensitive to alcohol intake | roughly 8 to 61 U/L | Standard range only |
| Total bilirubin | Pigment the liver conjugates and clears into bile | roughly 0.1 to 1.2 mg/dL | Standard range only |
| Platelet count | Falls with portal hypertension and spleen enlargement | roughly 150 to 450 x10^9/L | Standard range only |
| INR | Clotting time, reflecting clotting factor production | roughly 0.8 to 1.1 | Standard range only |
| Sodium | Fluid handling, often low in advanced liver disease | 135 to 145 mmol/L | Standard range only |
| Total protein | Albumin plus the globulin fraction | roughly 6.0 to 8.3 g/dL | Standard range only |
Reference ranges vary by laboratory, assay, age and sex, so always read a result against the range printed on your own report. FitScript's optimal range is an optimization target, not a diagnostic cut-off, and a value inside or outside it does not establish a condition.
Read as a set, these tests answer three separate questions. Are liver cells being injured, which the enzymes address. Is bile flowing, which ALP, GGT and bilirubin address. Is the liver still manufacturing and clearing properly, which albumin, bilirubin, INR and the platelet count address between them. Advanced scarring tends to show itself in the third group rather than the first.
Enzymes report cell injury, not scar tissue, so they can look unremarkable in someone with advanced scarring and markedly raised in someone whose liver is inflamed but barely fibrotic.
ALT sits mostly inside liver cells and is the more liver-specific of the two transaminases. AST is present in liver, skeletal muscle, heart muscle and red blood cells, so a raised AST has more possible sources. The relationship between them is often more informative than either number. As chronic liver disease advances, the ratio of AST to ALT tends to rise, and clinicians read that shift alongside the platelet count rather than in isolation.
There is a second reason enzymes fade as a signal. Enzyme release depends on having liver cells to release it. When a substantial share of functioning tissue has been replaced by scar, there is simply less enzyme to leak, and values can settle back toward the reference range while the structural problem continues. A result that drifts from clearly raised to apparently normal is not automatically reassuring and deserves interpretation in context.
ALP and GGT describe a different pattern. Both rise when bile flow is obstructed or irritated, and GGT is particularly responsive to alcohol intake. A predominantly cholestatic pattern, meaning ALP and GGT raised out of proportion to ALT, points the workup toward the bile ducts rather than the hepatocytes.
Research suggests that combinations of blood markers, rather than any single enzyme, perform better for identifying steatohepatitis and assessing fibrosis in fatty liver disease 1. In practice that is the whole argument for reading a panel instead of one line of a report.
A platelet count that drifts down over time is one of the most useful blood clues to advanced liver scarring, because two mechanisms push it in the same direction.
The first is portal hypertension. As scarring raises the resistance to blood flowing through the liver, pressure backs up into the spleen, which enlarges and holds on to a larger share of circulating platelets. The second is production. The liver makes thrombopoietin, the signalling protein that tells the bone marrow to produce platelets, and a heavily scarred liver makes less of it. The result is a count that slides gradually, often while the person feels entirely well.
That is also why the platelet count anchors most blood-based fibrosis scores. Studies indicate that scoring systems built from routine results including the platelet count have been evaluated for staging liver fibrosis in people with fatty liver disease 2.
Read a single low platelet count carefully. Plenty of other things lower it, including recent viral illness, some medicines (ask your prescriber), immune conditions and bone marrow disorders, and laboratory clumping can produce a falsely low value on one sample. The observation that matters is a trend. A count that was comfortably mid-range a few years ago and now sits near or below the bottom of the reference range, in someone with a reason for chronic liver injury, is worth discussing with a clinician alongside the rest of the panel.
These three describe function rather than injury, and together they track how much reserve the liver still has.
Bilirubin is the pigment left over when red blood cells are broken down. The liver conjugates it and sends it out in bile. When that pathway is impaired, by scarring, by bile duct obstruction or by a very high rate of red cell breakdown, bilirubin accumulates, and above a certain level it becomes visible as yellowing of the eyes and skin. Laboratories often report total, direct and indirect fractions, because the split narrows the possibilities. A mildly raised indirect bilirubin with otherwise ordinary liver labs is frequently an inherited variation in bilirubin processing rather than liver disease.
INR, or prothrombin time, measures how quickly blood clots in a standardised test. Most clotting factors are built in the liver and have a short half-life, so a liver that has lost manufacturing capacity shows a rising INR relatively early. Because vitamin K status and some medicines also shift it (ask your prescriber), INR is read alongside albumin rather than alone.
Sodium gets less attention than it deserves. In advanced liver disease, circulatory and hormonal changes cause the body to hold on to water out of proportion to salt, so the measured sodium concentration falls even though total body water has increased. A low sodium in this setting is a signal about fluid handling, not a reason to change salt intake on your own.
Clinicians combine several of these values into structured scores, such as Child-Pugh and MELD, which use function tests to describe severity and to guide specialist decisions. Those scores are tools for the clinical team rather than numbers to self-calculate.
Fibrosis scores combine results you probably already have, age, AST, ALT and the platelet count in the case of FIB-4, into a single number that sorts people into lower and higher likelihood of advanced scarring.
The logic is simple. Advanced fibrosis tends to lower platelets and to raise AST relative to ALT, so a formula that rewards both shifts separates groups better than either value alone. APRI works on a similar principle using AST and platelets. Most of these scores have two thresholds rather than one. Below the lower threshold, advanced fibrosis is unlikely and the clinician may simply plan follow-up. Above the upper threshold, the likelihood is high enough to warrant further assessment. Between them sits a grey zone where the score does not settle the question and another test is added.
Research suggests that non-invasive scoring systems calculated from routine blood results have been assessed for accuracy in staging fibrosis in people with non-alcoholic fatty liver disease 2. In people with chronic hepatitis B, non-invasive tests including blood-based scores and elastography were evaluated for staging fibrosis and cirrhosis in a systematic review and meta-analysis carried out to inform WHO guidance 3. Non-invasive methods for assessing and monitoring fibrosis and cirrhosis in chronic liver disease have also been examined as alternatives to biopsy, including their cost-effectiveness 4.
Two practical cautions. A score is only as good as the inputs, so a platelet count affected by an unrelated illness distorts it. And a score estimates a probability of a fibrosis stage, it does not establish a diagnosis. The output belongs in a conversation with a clinician who knows the cause of injury, the symptoms and the imaging.
Elastography measures how stiff the liver is, and stiffness rises as scar tissue accumulates, so it answers a structural question that blood tests can only approach indirectly.
The principle is mechanical. A probe sends a pulse or shear wave into the liver and the device measures how fast that wave travels through the tissue. Fast travel means stiff tissue. The result comes back in kilopascals and is read against thresholds that depend on the underlying cause of liver disease. Ultrasound-based and MRI-based versions exist, and the choice depends on body habitus, availability and what else the clinician wants to see. The scan is painless and takes minutes, and there is no sample to send away.
Imaging-based assessment for staging liver fibrosis in chronic liver disease was reviewed systematically in work supporting a professional practice guideline 5, and qualitative and quantitative imaging biomarkers have been described for the non-invasive identification of cirrhosis 6. Non-invasive approaches of this kind have been evaluated as part of monitoring strategies in chronic liver disease 4.
The usual sequence in practice is blood first, imaging second. A blood-based score is cheap and uses results that already exist, so it works well as a first filter. Elastography then resolves the people the score could not place, and specialist assessment follows for those whose results point toward advanced disease. Readings can be affected by eating shortly beforehand, by acute inflammation and by fluid in the abdomen, which is why the person performing the scan asks about those things.
Beyond the standard panel, several circulating markers have been examined for what they add in advanced disease, mainly around predicting the course rather than making the initial call.
In people with decompensated cirrhosis, a range of novel circulating markers has been examined for prognostic value in a systematic review and meta-analysis 7. Adiponectin, a hormone released by fat tissue, is associated with liver cirrhosis as assessed in a systematic review and meta-analysis of its use as a biomarker 8. Serum bile acids have been evaluated as metabolite markers with predictive value for liver cirrhosis 9, which fits the biology, since bile acids circulate through the liver and accumulate when that circuit is disrupted. Serum cytokines, adipokines and ferritin have been reviewed as non-invasive indicators of liver fibrosis in chronic liver disease 10.
What this means for a reader looking at their own results is modest but real. Most of these markers are not part of a routine liver panel, and a single value from one of them does not change what the standard tests show. They matter mainly because they illustrate that liver assessment keeps moving toward blood-based and imaging-based methods rather than tissue sampling. If one of them appears on a report, the next step is the same as for any other result, which is to ask the clinician what it adds to the overall picture rather than to interpret it alone.
No. Blood work can make advanced scarring much more or much less likely, but a cirrhosis diagnosis rests on the whole assessment, which combines labs, imaging, the cause of liver injury and, in selected cases, a tissue sample.
The reason is that no blood test measures scar tissue directly. Every blood signal discussed on this page is downstream. Platelets fall because pressure has risen somewhere else. Albumin falls because manufacturing capacity has dropped. Bilirubin rises because clearance has slowed. Each of those can be produced by something other than liver scarring, and scarring can be present without producing any of them yet.
The practical pathway is layered. A suggestive pattern on routine labs, or a risk factor such as long-term alcohol intake, metabolic disease or chronic viral hepatitis, triggers a blood-based score. The score sorts people by likelihood. Imaging, including elastography and standard ultrasound, assesses structure, and qualitative and quantitative imaging biomarkers have been described for identifying cirrhosis without biopsy 6. A specialist then decides whether anything further is required and what the cause is, because establishing the cause changes what happens next. Any management that follows is decided by the clinical team, and treatment decisions belong to a licensed provider.
Plenty, which is why a single out-of-range value is a prompt to look again rather than a conclusion.
Intense exercise in the days before a draw can raise AST and, to a lesser degree, ALT, because skeletal muscle contains both. Checking creatine kinase alongside them helps separate a muscle source from a liver source. Alcohol intake close to the test influences GGT in particular. Acute illness and systemic inflammation lower albumin regardless of liver status, and dehydration can nudge several concentrations upward at once.
Sample handling matters as well. Red cells damaged during collection release their contents, which can raise AST and bilirubin on the report without reflecting anything happening in the body. Platelet clumping in the collection tube can produce a falsely low count that resolves when the sample is repeated.
Some medicines and supplements affect liver enzymes, bilirubin or clotting time; ask your prescriber about anything you take before assuming a result reflects the liver itself. Inherited variations in bilirubin processing produce a mildly raised bilirubin that fluctuates with fasting or illness while everything else stays ordinary. Thyroid, kidney and gut conditions can shift individual lines on a liver panel too.
The useful habit is consistency. Testing under similar conditions, similar time of day, similar recent activity and similar fasting state, makes the trend across reports far easier to read than any single snapshot.
Symptoms and labs answer different questions, and advanced liver disease is often identified when the two are read together rather than separately.
Early on, the picture is vague. Persistent fatigue, reduced appetite, mild nausea and discomfort under the right ribs are common and non-specific. As function declines, more recognisable signs appear, including yellowing of the eyes or skin, dark urine, pale stools, generalised itching, easy bruising, swelling in the ankles or abdomen, small spider-like blood vessels on the skin, reddened palms, and changes in concentration, sleep pattern or memory.
The pairing is what makes each one informative. Swelling in the abdomen alongside a low albumin and a low platelet count tells a different story than swelling with an entirely ordinary panel. Itching with a raised ALP points toward bile flow. Confusion in someone already known to have liver disease is a reason to seek care promptly rather than to wait for the next scheduled test.
If you notice a cluster of these changes, write down when they started and what makes them better or worse, and bring that record to the appointment. Clinicians weight symptom timing heavily, because a pattern that developed over weeks is handled differently from one that developed over years.
Because the liver has substantial functional reserve, and the routine panel measures output rather than structure.
A liver can lose a large share of its working tissue and still produce enough albumin and clotting factors to keep those numbers inside the reference range. Enzyme leakage is intermittent, so a panel drawn during a quiet period looks different from one drawn during a flare. And as noted earlier, fewer functioning cells means less enzyme available to leak, so the most advanced disease sometimes produces the least impressive enzyme numbers. This is the state clinicians call compensated, and it is the reason screening in people with known risk factors relies on scores and imaging rather than waiting for the panel to turn.
Studies indicate that non-invasive tests have been assessed separately by underlying cause, including in people with chronic hepatitis B, because test performance depends on the disease behind the scarring 3.
The practical takeaway is about trend and context. A normal liver panel in someone with no risk factors and no symptoms is reassuring. The same panel in someone with long-standing metabolic disease, chronic viral hepatitis or sustained alcohol intake answers a narrower question, and the clinician may still want a fibrosis score or a scan.
It is a standard venous blood draw, usually one or two tubes, and most liver panels do not require fasting unless they are bundled with tests that do.
The enzymes, bilirubin, albumin and total protein come from a serum tube, the platelet count from a separate tube, and INR from a separate citrate tube that has to be filled to the mark for the result to be valid. Results typically come back within a day or two. If you are asked to fast, it is normally because glucose, insulin or lipids are being run at the same time.
Repeat intervals are set by the clinician, not by a fixed calendar, and they depend on the cause of injury, the stage, and whether anything has changed since the last draw. Someone being watched for slowly progressing fibrosis is monitored differently from someone whose labs shifted last month. What matters for interpretation is comparability over time, so using the same laboratory where possible keeps assay differences out of the trend.
For people tracking liver markers as part of broader health data, FitScript's membership covers 150+ biomarkers tested per year, with results interpreted by Atlas, the AI health advisor, and any treatment decisions belonging to a licensed provider.
Some findings justify contacting a clinician promptly rather than waiting for a routine appointment.
Those include new yellowing of the eyes or skin, a bilirubin that has risen sharply since the last test, a rising INR without another explanation, a platelet count that has fallen clearly below the reference range, new or rapidly increasing abdominal swelling, black or tarry stools, vomiting blood, and any new confusion, disorientation or marked drowsiness in a person with known liver disease. Severe abdominal pain with fever in someone with abdominal fluid also warrants same-day assessment.
More gradual findings still deserve attention, just on a different timeline. A suboptimal albumin, a mildly raised bilirubin, enzymes that have stayed outside the reference range across two or three draws, or a fibrosis score in the higher band are all reasons to book a review and bring the full set of reports.
Two closing points. Never ignore an abnormal liver result because you feel well, since compensated disease is specifically the state where someone feels well. And discuss your results and any treatment with a clinician or licensed provider, who can weigh the pattern against your history, your medicines and your imaging.
For the symptom side of the same picture, the guide to cirrhosis symptoms covers what people tend to notice and when it matters, and if you want a line-by-line explanation of the enzymes and proteins on a standard panel, read what do liver function tests show.
Blood tests can make advanced liver scarring much more or much less likely, but they do not confirm it on their own. The panel measures downstream effects such as protein production, bilirubin clearance and platelet count rather than the scar tissue itself. Confirmation comes from combining labs with imaging, the underlying cause and specialist assessment.
The pattern most often described includes a lower platelet count, a lower albumin, a higher bilirubin and a longer clotting time, with AST frequently higher than ALT. Enzymes may be only mildly raised or even inside the reference range, because fewer working liver cells means less enzyme to leak. Any single value needs interpretation alongside the others and your history.
Yes. Enzyme levels reflect ongoing cell injury, and that injury can be intermittent or reduced once a large share of liver tissue has already been replaced by scar. This is one reason a normal ALT and AST should not be read as a clean bill of liver health in someone with known risk factors.
FIB-4 is a score calculated from age, AST, ALT and the platelet count, all of which usually appear on routine bloods. It sorts people into a lower likelihood group, a higher likelihood group and a middle band where the score does not settle the question. A clinician decides what the result means for you and whether a scan is the sensible next step.
Most liver panels do not require fasting. You may be asked to fast if glucose, insulin or lipids are being drawn at the same appointment. Avoiding alcohol and hard exercise in the days before the draw makes the enzyme results easier to compare with previous reports.
A low albumin means the measured protein is below the laboratory reference range, and it may reflect reduced liver production, inflammation, low protein intake or protein loss through the kidneys or gut. It is not liver-specific, so it is read alongside bilirubin, clotting time and the platelet count. A clinician decides what further testing, if any, the result warrants.
There is no single schedule. The interval depends on the cause of the liver injury, the stage, your symptoms and what the last set of results showed, and it is set by the clinician managing your care. Using the same laboratory where possible makes the trend across reports easier to compare.
New yellowing of the eyes or skin, a sharp rise in bilirubin, a lengthening clotting time, a clearly falling platelet count, new abdominal swelling, black stools, vomiting blood or new confusion are all worth discussing with a clinician promptly. Do not ignore an abnormal liver result because you feel well, since early scarring is often silent. Bring your full set of reports so the pattern can be read over time.